Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
15.56 USD 2.35 ( 17.79%)
Last update at 2026-11-06T21:00:00Z
VOLUME
26916
Market Cap
7.03M

Momentum Score

…

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.70
Low
16.44
High
52 Week Price Range
0.57
Low
2.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

InMed Pharmaceuticals is a biotechnology company focused on developing cannabinoid-based therapeutics and on biosynthetic production methods for rare cannabinoids. Long-term growth may be supported by advancement of its R&D programs, scalable biosynthesis technology, and potential licensing or commercial partnerships that could enable broader supply and market access. Investors may find exposure to novel cannabinoid drug development and supply-chain innovation appealing as the therapeutic niche matures.

Material risks include high clinical and regulatory failure risk, limited operating history and financing needs that could lead to dilution, competition from larger pharmaceutical and specialty chemical companies, and uncertain commercial adoption of cannabinoid therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.21
Dividend Yield
-
Revenue TTM
4.94M
Revenue Per Share
1.47
Gross Profit TTM
1.71M
Debt / Equity
0.06
ROE
-112.65%
Net Debt
-2194.41M
ROCE
-0.92%
Diluted EPS TTM
-2.80

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -11.37M -8.16M -7.67M -7.93M -18.60M
Net income -12.56M -8.16M -7.68M -7.95M -23.41M
Selling general administrative 1880.23M 6.56M 5.80M 5.85M 6.87M
Selling and marketing expenses - - 5245.46M - -
Gross profit 709.84M 1.71M 1.10M 1.40M 0.54M
Reconciled depreciation 0.71M 0.53M 0.60M 0.60M 0.51M
Ebit -9.90M -7.79M -7.67M -8.33M -13.70M
Ebitda -9.19M -7.26M -7.06M -7.73M -13.18M
Depreciation and amortization 0.71M 0.53M 0.60M 0.60M 0.51M
Operating income -9.90M -7.92M -8.13M -8176.54M -13.70M
Other operating expenses 9.90M 12.86M 12.73M 12.51M 14.88M
Interest expense 0.01M 0.37M 0.00M - 0.10M
Tax provision 0.00M 0.00M 0.01M 0.01M -
Interest income 0.24M 0.16M 0.53M 0.49M 0.10M
Net interest income 0.23M -0.22M 0.53M 0.49M 0.10M
Income tax expense - - 0.01M 0.01M 4.81M
Total revenue 3176.50M 4.94M 4.60M 4.14M 1.09M
Total operating expenses 9.19M 9.62M 9.24M 9.78M 14.34M
Cost of revenue 2466.65M 3.24M 3.50M 2.73M 0.55M
Total other income expense net -1.48M -0.24M 0.47M -0.05M -4.90M
Net income from continuing ops -11.37M -8.16M -7.68M -7.95M -18.60M
Net income applicable to common shares - - - -7.95M -18.60M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 3030.07M 21.23M 11.82M 14.11M 12.79M
Intangible assets - 2.21M 1.78M 1.95M 2.11M
Other current assets 442.62M 0.50M 0.48M 0.50M 0.80M
Total liab 1955.06M 2.92M 2.62M 2.02M 3.71M
Total stockholder equity 1.08M 18.30M 9.21M 12.09M 9.08M
Other current liab 1954.13M 1.41M 1.03M 2000.62M 1.75M
Common stock 94.28M 124.28M 82.78M 77.62M 70.72M
Capital stock 94.28M 91.22M 82.78M 77.62M 70.72M
Retained earnings -130.23M -159.73M -109.08M -101.40M -93.45M
Good will - - - - 2.02M
Other assets - - - 0.10M 7.10M
Cash 2194.41M 15.09M 6.57M 8.91M 6.18M
Total current liabilities 1955.06M 2.51M 1.97M 2.00M 3.32M
Current deferred revenue - - -0.94M -1999.54M -
Net debt -2194.41M -14.08M -5.61M -8.52M -5.38M
Short term debt - 0.59M 0.32M 0.38M 0.40M
Short long term debt total - 1.01M 0.96M 0.39M 0.79M
Other stockholder equity 36.89M 53.57M 35.37M 35.74M 31.68M
Property plant equipment - - - 0.72M 0.90M
Total current assets 2676.71M 17.53M 8.69M 11.33M 9.60M
Net tangible assets - - - 10.14M 6.97M
Short term investments 39.67M 0.04M 43.06M 44.42M 0.04M
Net receivables - 0.63M 0.35M 0.26M 0.09M
Inventory - 1.31M 1.24M 1.62M 2.49M
Accounts payable 0.93M 0.50M 0.63M 0.54M 1.17M
Accumulated other comprehensive income 0.13M 0.18M 0.13M 0.13M 0.13M
Non currrent assets other 132.32M 0.14M 0.10M 0.10M 0.18M
Non current assets total 353.36M 3.70M 3.13M 2.77M 3.19M
Capital lease obligations 0.00M 0.74M 0.96M 0.39M 0.79M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments 0.00M 0.00M -0.01M -0.66M -0.67M
Change to liabilities - - - -0.81M -0.82M
Total cashflows from investing activities - - -0.01M -0.66M -0.67M
Net borrowings - - - - -0.29M
Total cash from financing activities 94.50M 12.27M 4.65M 10.68M 15.07M
Change to operating activities - - - -0.11M 0.13M
Net income -12560.85M -8.16M -7.68M -7.95M -18.60M
Change in cash -8549.02M 4.50M -2.34M 2.74M -1.19M
Begin period cash flow 10743.43M 6.57M 8.91M 6.18M 7.36M
End period cash flow 2194.41M 11.08M 6.57M 8.91M 6.18M
Total cash from operating activities -8643.51M -7.77M -6.99M -7.28M -15.58M
Issuance of capital stock 0.23M 8.13M 4.65M 12.00M 17.15M
Depreciation 708.36M 0.53M 0.60M 0.60M 0.51M
Other cashflows from investing activities - - -0.01M - -
Dividends paid 431.66M - - - -
Change to inventory - 0.28M 0.07M 0.57M -2.00M
Change to account receivables - -0.11M -0.09M -0.22M -0.04M
Other cashflows from financing activities 526.07M 4.14M -0.56M -1.32M -1.78M
Change to netincome - - - 0.63M 5.24M
Capital expenditures 0.00M 0.00M 0.01M 0.16M 0.04M
Change in working capital -0.08M -0.34M -0.37M -0.57M -2.73M
Stock based compensation 106.87M 0.12M 0.14M 0.28M 0.78M
Other non cash items 3102.19M 0.08M 0.32M -0.00M 4.46M
Free cash flow -8643.51M -7.77M -7.00M -7.45M -15.62M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INM
InMed Pharmaceuticals Inc		 2.35
17.79%		 15.56 - - 1.42 6.64 0.46 0.51
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8

604 669 7207

https://www.inmedpharma.com

13

Name Title Year Born
Mr. Eric A. Adams B.S. Chem., M.I.B. Pres, CEO & Director 1964
Ms. Alexandra Diane-Janet Mancini M.Sc. Sr. VP of Clinical & Regulatory Affairs 1953
Dr. Eric Chih-Hsien Hsu Sr. VP of Preclinical R&D 1970
Dr. Sazzad Hossain M.Sc., Ph.D. Co-Founder 1958
Ms. Sarah Li CPA, CGA VP of Accounting & Controller NA
Mr. Michael Woudenberg P.Eng. Chief Operating Officer 1969
Colin Clancy Sr. Director of Investor Relations NA
Mr. Jerry P. Griffin VP of Sales & Marketing NA
Dr. Shane A. Johnson Ph.D. Sr. VP & GM of BayMedica NA
Dr. Ado Muhammad Sr. Consultant of Medical Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…